O	O	0	12	Phenylarsine	Phenylarsine	B-NP	NN	O	2	NMOD	O
O	O	13	18	oxide	oxide	I-NP	NN	O	3	SUB	O
O	O	19	27	inhibits	inhibit	B-VP	VBZ	O	0	ROOT	O
O	O	28	30	ex	ex	B-NP	FW	O	5	AMOD	O
O	O	31	35	vivo	vivo	I-NP	FW	O	9	NMOD	O
O	O	36	39	HIV	HIV	I-NP	NN	O	9	NMOD	O
O	O	39	40	-	-	B-NP	HYPH	O	9	NMOD	O
O	O	40	41	1	1	I-NP	CD	O	9	NMOD	O
O	O	42	52	expression	expression	I-NP	NN	O	3	OBJ	O
O	O	52	53	.	.	O	.	O	3	P	O

O	O	55	67	Phenylarsine	Phenylarsine	B-NP	NN	O	2	NMOD	O
O	O	68	73	oxide	oxide	I-NP	NN	O	18	SUB	O
O	O	74	75	(	(	O	(	O	5	DEP	O
O	O	75	78	PAO	PAO	B-NP	NN	O	5	DEP	O
O	O	78	79	)	)	O	)	O	2	NMOD	O
O	O	79	80	,	,	O	,	O	2	P	O
O	O	81	86	which	which	B-NP	WDT	O	2	NMOD	O
O	O	87	89	is	be	B-VP	VBZ	O	7	SBAR	O
O	O	90	99	described	describe	I-VP	VBN	O	8	VC	O
O	O	100	102	as	as	B-PP	IN	O	9	VMOD	O
O	O	103	105	an	an	B-NP	DT	O	12	NMOD	O
O	O	106	115	inhibitor	inhibitor	I-NP	NN	O	10	PMOD	O
O	O	116	118	of	of	B-PP	IN	O	12	NMOD	O
T4	B-Entity	119	127	tyrosine	tyrosine	B-NP	NN	B-protein	16	NMOD	B-protein
O	O	128	139	phosphatase	phosphatase	I-NP	NN	I-protein	16	NMOD	I-protein
O	O	140	148	activity	activity	I-NP	NN	O	13	PMOD	O
O	O	148	149	,	,	O	,	O	2	P	O
O	O	150	158	inhibits	inhibit	B-VP	VBZ	O	0	ROOT	O
O	O	159	163	H2O2	H2O2	B-NP	NN	O	20	NMOD	O
O	O	164	171	release	release	I-NP	NN	O	18	OBJ	O
O	O	172	176	from	from	B-PP	IN	O	20	NMOD	O
O	O	177	182	human	human	B-NP	JJ	B-cell_type	26	NMOD	B-cell_type
O	O	183	193	peripheral	peripheral	I-NP	JJ	I-cell_type	26	NMOD	I-cell_type
O	O	194	199	blood	blood	I-NP	NN	I-cell_type	26	NMOD	I-cell_type
O	O	200	211	mononuclear	mononuclear	I-NP	JJ	I-cell_type	26	NMOD	I-cell_type
O	O	212	217	cells	cell	I-NP	NNS	I-cell_type	21	PMOD	I-cell_type
O	O	218	219	(	(	O	(	O	29	DEP	O
O	O	219	224	PBMCs	PBMC	B-NP	NNS	B-cell_type	29	DEP	B-cell_type
O	O	224	225	)	)	O	)	O	26	NMOD	O
O	O	226	228	as	as	B-SBAR	IN	O	18	VMOD	O
O	O	229	237	measured	measure	B-VP	VBN	O	30	SBAR	O
O	O	238	240	by	by	B-PP	IN	O	31	VMOD	O
O	O	241	257	electrochemistry	electrochemistry	B-NP	NN	O	32	PMOD	O
O	O	257	258	.	.	O	.	O	18	P	O

O	O	259	264	Since	Since	B-SBAR	IN	O	40	VMOD	O
O	O	265	270	human	human	B-NP	JJ	O	5	NMOD	O
O	O	271	287	immunodeficiency	immunodeficiency	I-NP	NN	O	5	NMOD	O
O	O	288	293	virus	virus	I-NP	NN	O	5	NMOD	O
O	O	294	298	type	type	I-NP	NN	O	12	NMOD	O
O	O	299	300	1	1	I-NP	CD	O	5	NMOD	O
O	O	301	302	(	(	O	(	O	11	DEP	O
O	O	302	305	HIV	HIV	O	NN	O	11	DEP	O
O	O	305	306	-	-	O	HYPH	O	10	P	O
O	O	306	307	1	1	O	CD	O	11	DEP	O
O	O	307	308	)	)	O	)	O	5	NMOD	O
O	O	309	320	replication	replication	B-NP	NN	O	13	SUB	O
O	O	321	323	is	be	B-VP	VBZ	O	1	SBAR	O
O	O	324	329	known	know	I-VP	VBN	O	13	VC	O
O	O	330	332	to	to	I-VP	TO	O	16	VMOD	O
O	O	333	335	be	be	I-VP	VB	O	14	VMOD	O
O	O	336	343	favored	favor	I-VP	VBN	O	16	VC	O
O	O	344	349	under	under	B-PP	IN	O	17	VMOD	O
O	O	350	359	oxidative	oxidative	B-NP	JJ	O	21	NMOD	O
O	O	360	366	stress	stress	I-NP	NN	O	21	NMOD	O
O	O	367	377	conditions	condition	I-NP	NNS	O	18	PMOD	O
O	O	377	378	,	,	O	,	O	40	P	O
O	O	379	381	ex	ex	B-NP	FW	O	24	AMOD	O
O	O	382	386	vivo	vivo	I-NP	FW	O	25	NMOD	O
O	O	387	398	experiments	experiment	I-NP	NNS	O	39	NMOD	O
O	O	399	404	using	use	B-VP	VBG	O	25	NMOD	O
O	O	405	415	uninfected	uninfected	B-NP	JJ	O	28	NMOD	O
O	O	416	421	PBMCs	PBMC	I-NP	NNS	B-cell_type	26	OBJ	B-cell_type
O	O	421	422	,	,	O	,	O	39	P	O
O	O	423	430	primary	primary	B-NP	JJ	B-cell_type	31	NMOD	B-cell_type
O	O	431	440	monocytes	monocyte	I-NP	NNS	I-cell_type	39	NMOD	I-cell_type
O	O	441	443	or	or	O	CC	O	39	NMOD	O
O	O	444	445	a	a	B-NP	DT	O	39	NMOD	O
O	O	446	454	latently	latently	I-NP	RB	O	35	AMOD	O
O	O	455	463	infected	infected	I-NP	JJ	O	39	NMOD	O
O	O	464	476	promonocytic	promonocytic	I-NP	JJ	B-cell_line	39	NMOD	B-cell_line
O	O	477	479	U1	U1	I-NP	NN	I-cell_line	39	NMOD	I-cell_line
O	O	480	484	cell	cell	I-NP	NN	I-cell_line	39	NMOD	I-cell_line
O	O	485	489	line	line	I-NP	NN	I-cell_line	40	SUB	I-cell_line
O	O	490	494	show	show	B-VP	VBP	O	0	ROOT	O
O	O	495	499	that	that	B-SBAR	IN	O	40	VMOD	O
O	O	500	503	HIV	HIV	B-NP	NN	O	45	NMOD	O
O	O	503	504	-	-	B-NP	HYPH	O	45	NMOD	O
O	O	504	505	1	1	I-NP	CD	O	45	NMOD	O
O	O	506	517	replication	replication	I-NP	NN	O	47	NMOD	O
O	O	518	521	and	and	I-NP	CC	O	47	NMOD	O
O	O	522	534	reactivation	reactivation	I-NP	NN	O	55	SUB	O
O	O	534	535	,	,	O	,	O	47	P	O
O	O	536	545	monitored	monitor	B-VP	VBN	O	47	NMOD	O
O	O	546	548	by	by	B-PP	IN	O	49	VMOD	O
T1	B-Protein	549	552	p24	p24	B-NP	NN	B-protein	52	NMOD	B-protein
T1	I-Protein	553	560	antigen	antigen	I-NP	NN	I-protein	53	NMOD	I-protein
O	O	561	572	measurement	measurement	I-NP	NN	O	50	PMOD	O
O	O	572	573	,	,	O	,	O	47	P	O
O	O	574	577	are	be	B-VP	VBP	O	41	SBAR	O
O	O	578	587	inhibited	inhibit	I-VP	VBN	O	55	VC	O
O	O	588	590	by	by	B-PP	IN	O	56	VMOD	O
O	O	591	594	PAO	PAO	B-NP	NN	O	57	PMOD	O
O	O	595	597	in	in	B-PP	IN	O	56	VMOD	O
O	O	598	599	a	a	B-NP	DT	O	67	NMOD	O
O	O	600	604	time	time	I-NP	NN	O	67	NMOD	O
O	O	604	605	-	-	B-NP	HYPH	O	67	NMOD	O
O	O	606	609	and	and	I-NP	CC	O	67	NMOD	O
O	O	610	623	concentration	concentration	I-NP	NN	O	67	NMOD	O
O	O	623	624	-	-	I-NP	HYPH	O	67	NMOD	O
O	O	624	633	dependent	dependent	I-NP	JJ	O	67	NMOD	O
O	O	634	640	manner	manner	I-NP	NN	O	59	PMOD	O
O	O	640	641	.	.	O	.	O	40	P	O

O	O	642	647	These	These	B-NP	DT	O	2	NMOD	O
O	O	648	660	observations	observation	I-NP	NNS	O	3	SUB	O
O	O	661	664	can	can	B-VP	MD	O	0	ROOT	O
O	O	665	667	be	be	I-VP	VB	O	3	VC	O
O	O	668	674	linked	link	I-VP	VBN	O	4	VC	O
O	O	675	679	with	with	B-PP	IN	O	5	VMOD	O
O	O	680	683	the	the	B-NP	DT	O	8	NMOD	O
O	O	684	694	inhibition	inhibition	I-NP	NN	O	6	PMOD	O
O	O	695	697	of	of	B-PP	IN	O	8	NMOD	O
T5	B-Entity	698	700	NF	NF	B-NP	NN	B-protein	13	NMOD	B-protein
T5	I-Entity	700	701	-	-	B-NP	HYPH	I-protein	13	NMOD	I-protein
T5	I-Entity	701	706	kappa	kappa	I-NP	NN	I-protein	13	NMOD	I-protein
T5	I-Entity	707	708	B	B	I-NP	NN	I-protein	14	NMOD	I-protein
O	O	709	719	activation	activation	I-NP	NN	O	9	PMOD	O
O	O	720	724	when	when	B-ADVP	WRB	O	5	VMOD	O
O	O	725	735	uninfected	uninfected	B-NP	JJ	B-cell_type	17	NMOD	B-cell_type
O	O	736	745	monocytes	monocyte	I-NP	NNS	I-cell_type	18	SUB	I-cell_type
O	O	746	749	are	be	B-VP	VBP	O	15	SBAR	O
O	O	750	757	induced	induce	I-VP	VBN	O	18	VC	O
O	O	758	760	by	by	B-PP	IN	O	19	VMOD	O
O	O	761	767	either	either	O	CC	O	31	NMOD	O
T2	B-Protein	768	773	tumor	tumor	B-NP	NN	B-protein	25	NMOD	B-protein
T2	I-Protein	774	782	necrosis	necrosis	I-NP	NN	I-protein	25	NMOD	I-protein
T2	I-Protein	783	789	factor	factor	I-NP	NN	I-protein	25	NMOD	I-protein
T2	I-Protein	790	795	alpha	alpha	I-NP	NN	I-protein	31	NMOD	I-protein
O	O	796	797	(	(	O	(	O	30	DEP	O
T3	B-Protein	797	800	TNF	TNF	B-NP	NN	B-protein	29	NMOD	B-protein
T3	I-Protein	800	801	-	-	O	HYPH	O	29	P	O
T3	I-Protein	801	806	alpha	alpha	O	SYM	O	30	DEP	O
O	O	806	807	)	)	O	)	O	25	NMOD	O
O	O	808	815	phorbol	phorbol	B-NP	NN	O	37	NMOD	O
O	O	816	818	12	12	I-NP	CD	O	31	NMOD	O
O	O	818	819	-	-	O	HYPH	O	37	NMOD	O
O	O	819	828	myristate	myristate	B-NP	NN	B-protein	37	NMOD	B-protein
O	O	829	831	13	13	I-NP	CD	I-protein	34	NMOD	I-protein
O	O	831	832	-	-	O	HYPH	O	34	P	O
O	O	832	839	acetate	acetate	B-NP	NN	O	42	NMOD	O
O	O	840	841	(	(	O	(	O	40	DEP	O
O	O	841	844	PMA	PMA	B-NP	NN	O	40	DEP	O
O	O	844	845	)	)	O	)	O	37	NMOD	O
O	O	846	848	or	or	O	CC	O	42	NMOD	O
O	O	849	867	lipopolysaccharide	lipopolysaccharide	B-NP	NN	O	20	PMOD	O
O	O	868	869	(	(	O	(	O	45	DEP	O
O	O	869	872	LPS	LPS	B-NP	NN	O	45	DEP	O
O	O	872	873	)	)	O	)	O	42	NMOD	O
O	O	873	874	.	.	O	.	O	3	P	O
